MT 0169
Alternative Names: MT-0169; TAK-169Latest Information Update: 07 May 2025
At a glance
- Originator Molecular Templates; Takeda Oncology
- Class Antineoplastics; Bacterial toxins; Immunoglobulin fragments; Immunotoxins; Recombinant fusion proteins
- Mechanism of Action Proteasome inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 07 May 2025 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (Molecular Templates website, May 2025)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Second-line therapy or greater) in USA (IV, Infusion)
- 30 Oct 2024 M.D. Anderson Cancer Center withdraws a planned phase-I clinical trial in Acute myeloid leukaemia (Second-line therapy or greater) prior to enrollment initiation due to the PI request (NCT06522373)